SANKYO/PARKE-DAVIS JOINT VENTURE TO PROMOTE ACCUPRIL ACE INHIBITOR AND TROGLITAZONE ANTIDIABETIC; PROVIDES PLATFORM FOR FUTURE SANKYO LAUNCHES IN U.S.

Warner-Lambert is sharing its top-selling drug (Accupril) with Sankyo to ensure an exclusive position for marketing the pending antidiabetic troglitazone in the U.S.